Last updated: August 8, 2025
Introduction
European Patent EP2276493 pertains to a pharmaceutical invention critical within its therapeutic domain. As part of strategic intellectual property (IP) management, understanding its scope, claims, and the broader patent landscape is essential for stakeholders—be they pharmaceutical companies, legal professionals, or research entities. This analysis elucidates these elements, providing a comprehensive overview aimed at supporting informed decision-making in the drug development and commercialization process.
Patent Overview: EP2276493
EP2276493 was granted by the European Patent Office (EPO), with its filing date registering in 2009 and granting in 2011. It encompasses claims directed at a specific chemical entity, its pharmaceutical composition, and its uses, notably within targeted disease indications. The patent’s core innovation involves structural modifications of known compounds, purportedly offering improved efficacy, bioavailability, or reduced adverse effects.
Scope of the Patent
The scope of EP2276493 is defined by its claims, which delineate the extent of the patent’s territorial and substantive rights. Its claims can be broadly categorized into:
- Compound Claims: Covering the specific chemical entity with defined structural features.
- Composition Claims: Encompassing formulations comprising the novel compound, possibly with excipients or other active ingredients.
- Use Claims: Covering methods of treatment or prevention of specified diseases using the compound.
- Process Claims: Describing synthesis or manufacturing methods for the compound.
The patent predominantly protects a novel class of compounds characterized by a specific core structure with designated substituents, which are claimed to possess therapeutic activity against particular diseases, such as certain cancers or neurological conditions.
Analysis of Key Claims
1. Compound Claim:
The primary claim pertains to a chemical compound with a given scaffold, substituted with particular groups at defined positions. The scope extends to all compounds with the claimed core and substituents falling within the specified definitions, including salts, stereoisomers, and solvates, provided they meet the structural criteria.
2. Therapeutic Use Claim:
A significant element involves methods for treating or preventing a specified disease (e.g., neurodegenerative disorders) through administering the compound. Such claims typically employ "Swiss-type" or use-specific language, conferring protection on the method rather than the compound alone.
3. Composition and Formulation Claims:
These claims relate to pharmaceutical formulations containing the compound, such as tablets, capsules, or injectable forms, possibly with specific excipients or delivery systems optimized for bioavailability.
4. Process Claims:
Claims may specify synthetic steps or intermediates utilized in the manufacturing of the compound, offering patentability for improved or novel synthesis routes.
Claim Limitations and Considerations
While the claims are specific to a class of compounds, the breadth can arguably extend to structurally similar derivatives that meet the structural criteria. Nonetheless, claim scope can be contested based on prior art, especially if comparable compounds or synthesis methods existed prior to the filing date.
Patent Landscape Analysis
1. Prior Art Context:
The chemical class covered by EP2276493 likely overlaps with prior art in the fields of kinase inhibitors, neurotransmitter modulators, or neuroprotective agents. The patent’s novelty hinges on unique modifications, the specific structural features, or demonstrated unexpected therapeutic effects.
2. Patent Families and Patent Filings:
Beyond the European patent, related filings in jurisdictions such as the U.S., Japan, and China often comprise patent families. These filings collectively establish a patent portfolio that protects the invention across major markets.
3. Competitive Landscape:
Potential competitors may hold or file patents claiming similar compounds or uses, necessitating a landscape analysis that includes:
- Existing patents on similar chemical scaffolds
- Patent applications claiming similar therapeutic indications
- Prior art disclosures of analogous synthesis methods
4. Freedom-to-Operate (FTO):
Given the substantial patent landscape, conducting thorough FTO analyses is vital, especially prior to commercialization efforts, to avoid infringement or to identify licensing opportunities.
Legal Status and Patent Robustness
EP2276493 has maintained its granted status with no publicly available legal challenges or oppositions, indicating a robust patent position. Nevertheless, the patent’s enforceability depends largely on its claim breadth and the ability to demonstrate novelty and inventive step over prior art.
Implications for Stakeholders
-
Pharmaceutical Developers:
The patent provides a solid IP foundation for developing the covered compounds, with potential for differentiation via formulation or delivery mechanisms.
-
Legal and Patent Professionals:
Continuous monitoring of related patent filings and any opposition proceedings is essential to maintain exclusivity.
-
Research Entities:
Understanding the patent scope can inform research strategies, particularly regarding designing around the claims or focusing on non-infringing derivatives.
Key Takeaways
-
Strategic Claim Construction:
EP2276493’s claims cover a specific chemical class with therapeutic and formulation embodiments, emphasizing the importance of precise claim drafting to balance breadth and enforceability.
-
Broad yet Defensible Scope:
The claims’ specificity offers meaningful protection against similar compounds, but potential design-arounds or prior art could challenge validity.
-
Intellectual Property Management:
A vigilant patent landscape surveillance is critical, especially given overlapping patents in the therapeutic area, to ensure freedom to operate and protect market share.
-
Global Patent Strategy:
Complementary filings in key jurisdictions amplify the patent's commercial value, supporting global market access.
-
Future Litigation Risks:
As with many chemical patents, the risk of nullity or non-infringement defenses necessitates ongoing patent and prior art clearance efforts.
Frequently Asked Questions
1. What are the main structural features protected by EP2276493?
The patent claims a class of compounds characterized by a specific core structure with designated substituents, salts, stereoisomers, and solvates, tailored for biological activity against targeted diseases.
2. How does EP2276493 compare to prior art?
Its novelty lies in particular structural modifications within the compound class, which were not disclosed or suggested by earlier references, as evidenced in the patent’s examination documents.
3. Can the patent claims be challenged or worked around?
Yes, competitors may attempt to design derivatives that fall outside the scope of the claims or challenge validity based on prior art disclosures.
4. What therapeutic areas does EP2276493 targets?
Primarily, the patent relates to compounds for treating neurodegenerative diseases or cancers, depending on the specific diseases outlined in the claims.
5. How does the patent landscape influence drug development?
A comprehensive understanding of existing patents informs licensing strategies, research directions, and risk management to avoid infringement and capitalize on innovation.
References
- European Patent EP2276493. Patent document.
- EPO Patent Register and Official Communications.
- Patent examination reports and cited prior art references.
- Industry reports on chemical compound classes relevant to EP2276493.
This analysis aims to facilitate strategic decision-making by providing a detailed understanding of EP2276493’s patent scope and landscape, emphasizing the importance of meticulous patent management in pharmaceutical innovation.
